{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:25:53Z","timestamp":1791069953414,"version":"4.1.0"},"reference-count":44,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2018.0535","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T07:13:57Z","timestamp":1532589237000},"source":"Crossref","is-referenced-by-count":9,"title":["Hodgkin Lymphoma in Adults"],"prefix":"10.3238","author":[{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Eichenauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2018,8,6]]},"reference":[{"key":"10.3238\/arztebl.2018.0535_ref1","unstructured":"Robert Koch-Institut: Krebs in Deutschland. Zentrum f\u00fcr Krebsregisterdaten \u2013 (last accessed 11 April 2018)."},{"key":"10.3238\/arztebl.2018.0535_ref2","doi-asserted-by":"crossref","unstructured":"Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N: High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma. Cochrane Database Sys Rev 2013; 6: CD00941","DOI":"10.1002\/14651858.CD009411.pub2"},{"key":"10.3238\/arztebl.2018.0535_ref3","doi-asserted-by":"crossref","unstructured":"El-Galaly TC, d\u2018Amore F, Mylam KJ, et al.: Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30: 4508\u201314","DOI":"10.1200\/JCO.2012.42.4036"},{"key":"10.3238\/arztebl.2018.0535_ref4","doi-asserted-by":"crossref","unstructured":"Blank O, von Tresckow B, Monsef I, Specht L, Engert A, Skoetz N: Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2017; 4: Cd007110","DOI":"10.1002\/14651858.CD007110.pub3"},{"key":"10.3238\/arztebl.2018.0535_ref5","doi-asserted-by":"crossref","unstructured":"Engert A, Plutschow A, Eich HT, et al.: Reduced treatment intensity in patients with early-stage Hodgkin\u2018s lymphoma. N Engl J Med 2010; 363: 640\u201352","DOI":"10.1056\/NEJMoa1000067"},{"key":"10.3238\/arztebl.2018.0535_ref6","doi-asserted-by":"crossref","unstructured":"Behringer K, Goergen H, Hitz F, et al.: Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2018s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 2015; 385: 1418\u201327","DOI":"10.1016\/S0140-6736(14)61469-0"},{"key":"10.3238\/arztebl.2018.0535_ref7","doi-asserted-by":"crossref","unstructured":"Specht L, Yahalom J, Illidge T, et al.: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014; 89: 854\u201362","DOI":"10.1016\/j.ijrobp.2013.05.005"},{"key":"10.3238\/arztebl.2018.0535_ref8","doi-asserted-by":"crossref","unstructured":"Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N: Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane Database Syst Rev 2015; 1: Cd010533","DOI":"10.1002\/14651858.CD010533.pub2"},{"key":"10.3238\/arztebl.2018.0535_ref9","doi-asserted-by":"crossref","unstructured":"Andre MP, Girinsky T, Federico M, et al.: Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial. J Clin Oncol 2017; 35: 1786\u201394","DOI":"10.1200\/JCO.2016.68.6394"},{"key":"10.3238\/arztebl.2018.0535_ref10","doi-asserted-by":"crossref","unstructured":"Radford J, Illidge T, Counsell N, et al.: Results of a trial of PET-directed therapy for early-stage Hodgkin\u2018s lymphoma. N Engl J Med 2015; 17: 1598\u2013607","DOI":"10.1056\/NEJMoa1408648"},{"key":"10.3238\/arztebl.2018.0535_ref11","doi-asserted-by":"crossref","unstructured":"Sasse S, Brockelmann PJ, Goergen H, et al.: Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol 2017; 35: 1999\u20132007","DOI":"10.1200\/JCO.2016.70.9410"},{"key":"10.3238\/arztebl.2018.0535_ref12","doi-asserted-by":"crossref","unstructured":"Eich HT, Diehl V, Gorgen H, et al.: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2018s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199\u2013206","DOI":"10.1200\/JCO.2010.29.8018"},{"key":"10.3238\/arztebl.2018.0535_ref13","doi-asserted-by":"crossref","unstructured":"von Tresckow B, Plutschow A, Fuchs M, et al.: Dose-intensification in early unfavorable Hodgkin\u2018s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012; 30: 907\u201313","DOI":"10.1200\/JCO.2011.38.5807"},{"key":"10.3238\/arztebl.2018.0535_ref14","doi-asserted-by":"crossref","unstructured":"Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B: Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2017; 5: Cd007941","DOI":"10.1002\/14651858.CD007941.pub3"},{"key":"10.3238\/arztebl.2018.0535_ref15","doi-asserted-by":"crossref","unstructured":"Engert A, Haverkamp H, Kobe C, et al.: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2018s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791\u20139","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"10.3238\/arztebl.2018.0535_ref16","doi-asserted-by":"crossref","unstructured":"Skoetz N, Trelle S, Rancea M, et al.: Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2018s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 943\u201352","DOI":"10.1016\/S1470-2045(13)70341-3"},{"key":"10.3238\/arztebl.2018.0535_ref17","doi-asserted-by":"crossref","unstructured":"Borchmann P, Goergen H, Kobe C, et al.: PET-guided treatment in patients with advanced-stage Hodgkin\u2018s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390: 2790\u2013802","DOI":"10.1016\/S0140-6736(17)32134-7"},{"key":"10.3238\/arztebl.2018.0535_ref18","doi-asserted-by":"crossref","unstructured":"Wongso D, Fuchs M, Plutschow A, et al.: Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the German Hodgkin Study Group. J Clin Oncol 2013; 31: 2819\u201324","DOI":"10.1200\/JCO.2012.47.9774"},{"key":"10.3238\/arztebl.2018.0535_ref19","doi-asserted-by":"crossref","unstructured":"Ballova V, Ruffer JU, Haverkamp H, et al.: A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2018s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005; 16: 124\u201331","DOI":"10.1093\/annonc\/mdi023"},{"key":"10.3238\/arztebl.2018.0535_ref20","doi-asserted-by":"crossref","unstructured":"Boll B, Goergen H, Behringer K, et al.: Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood 2016; 127: 2189\u201392","DOI":"10.1182\/blood-2015-11-681064"},{"key":"10.3238\/arztebl.2018.0535_ref21","doi-asserted-by":"crossref","unstructured":"Boll B, Bredenfeld H, Gorgen H, et al.: Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 2011; 118: 6292\u20138","DOI":"10.1182\/blood-2011-07-368167"},{"key":"10.3238\/arztebl.2018.0535_ref22","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Engert A: Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematology Am Soc Hematol Educ Program 2017; 2017: 324\u20138.","DOI":"10.1182\/asheducation-2017.1.324"},{"key":"10.3238\/arztebl.2018.0535_ref23","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Plutschow A, Fuchs M, et al.: Long-term course of patients with stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol 2015; 33: 2857\u201362","DOI":"10.1200\/JCO.2014.60.4363"},{"key":"10.3238\/arztebl.2018.0535_ref24","doi-asserted-by":"crossref","unstructured":"Akhtar S, Montoto S, Boumendil A, et al.: High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European Society for Blood and Marrow Transplantation-Lymphoma Working Party. Am J Hematol 2018; 93: 40\u20136","DOI":"10.1002\/ajh.24927"},{"key":"10.3238\/arztebl.2018.0535_ref25","doi-asserted-by":"crossref","unstructured":"Eichenauer DA, Pluetschow A, Schroeder L, et al.: Relapsed nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group (GHSG). Blood 2016; 128: 922.","DOI":"10.1182\/blood.V128.22.922.922"},{"key":"10.3238\/arztebl.2018.0535_ref26","doi-asserted-by":"crossref","unstructured":"Schmitz N, Pfistner B, Sextro M, et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2018s disease: a randomised trial. Lancet 2002; 359: 2065\u201371","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"10.3238\/arztebl.2018.0535_ref27","doi-asserted-by":"crossref","unstructured":"Brockelmann PJ, Muller H, Casasnovas O, et al.: Risk factors and a prognostic score for survival after autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol 2017; 28: 1352\u2013135","DOI":"10.1093\/annonc\/mdx072"},{"key":"10.3238\/arztebl.2018.0535_ref28","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Schoder H, Yahalom J, et al.: PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin\u2018s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol 2015; 16: 284\u201392","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"10.3238\/arztebl.2018.0535_ref29","doi-asserted-by":"crossref","unstructured":"Sibon D, Morschhauser F, Resche-Rigon M, et al.: Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA\/SFGM-TC study group. Haematologica 2016; 101: 474\u201381","DOI":"10.3324\/haematol.2015.136408"},{"key":"10.3238\/arztebl.2018.0535_ref30","doi-asserted-by":"crossref","unstructured":"Younes A, Gopal AK, Smith SE, et al.: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2018s lymphoma. J Clin Oncol 2012; 30: 2183\u20139","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"10.3238\/arztebl.2018.0535_ref31","doi-asserted-by":"crossref","unstructured":"Younes A, Santoro A, Shipp M, et al.: Nivolumab for classical Hodgkin\u2018s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283\u20139","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"10.3238\/arztebl.2018.0535_ref32","doi-asserted-by":"crossref","unstructured":"Chen R, Zinzani PL, Fanale MA, et al.: Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 2017; 35: 2125\u201332","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"10.3238\/arztebl.2018.0535_ref33","doi-asserted-by":"crossref","unstructured":"Sureda A, Canals C, Arranz R, et al.: Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2018s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espanol de Linfomas\/Trasplante de Medula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012; 97: 310\u20137","DOI":"10.3324\/haematol.2011.045757"},{"key":"10.3238\/arztebl.2018.0535_ref34","doi-asserted-by":"crossref","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM, et al.: Second cancer risk up to 40 years after treatment for Hodgkin\u2018s lymphoma. N Engl J Med 2015; 373: 2499\u2013511","DOI":"10.1056\/NEJMoa1505949"},{"key":"10.3238\/arztebl.2018.0535_ref35","doi-asserted-by":"crossref","unstructured":"Behringer K, Goergen H, Muller H, et al.: Cancer-related fatigue in patients with and survivors of Hodgkin lymphoma: The impact on treatment outcome and social reintegration. J Clin Oncol 2016; 34: 4329\u201337","DOI":"10.1200\/JCO.2016.67.7450"},{"key":"10.3238\/arztebl.2018.0535_ref36","doi-asserted-by":"crossref","unstructured":"Kreissl S, Mueller H, Goergen H, et al.: Cancer-related fatigue in patients with and survivors of Hodgkin\u2018s lymphoma: a longitudinal study of the German Hodgkin Study Group. Lancet Oncol 2016; 17: 1453\u201362","DOI":"10.1016\/S1470-2045(16)30093-6"},{"key":"10.3238\/arztebl.2018.0535_ref37","doi-asserted-by":"crossref","unstructured":"Behringer K, Mueller H, Goergen H, et al.: Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 2013; 31: 231\u20139","DOI":"10.1200\/JCO.2012.44.3721"},{"key":"10.3238\/arztebl.2018.0535_ref38","doi-asserted-by":"crossref","unstructured":"Franklin J, Eichenauer DA, Becker I, Monsef I, Engert A: Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis. Cochrane Database Syst Rev 2017; 9: CD008814.","DOI":"10.1002\/14651858.CD008814.pub2"},{"key":"10.3238\/arztebl.2018.0535_ref39","doi-asserted-by":"crossref","unstructured":"Swerdlow AJ, Higgins CD, Smith P, et al.: Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206\u201314","DOI":"10.1093\/jnci\/djk029"},{"key":"10.3238\/arztebl.2018.0535_ref40","doi-asserted-by":"crossref","unstructured":"Hancock SL, Cox RS, McDougall IR: Thyroid diseases after treatment of Hodgkin\u2018s disease. N Engl J Med 1991; 325: 599\u2013605","DOI":"10.1056\/NEJM199108293250902"},{"key":"10.3238\/arztebl.2018.0535_ref41","unstructured":"Gemeinsamer Bundesausschuss: Richtlinie des Gemeinsamen Bundesausschusses zu Untersuchungs- und Behandlungsmethoden der vertrags\u00e4rztlichen Versorgung (Richtlinie Methoden vertrags\u00e4rztliche Versorgung) (last accessed 11 April 2018)."},{"key":"10.3238\/arztebl.2018.0535_ref42","unstructured":"Gemeinsamer Bundesausschuss: Richtlinie Methoden vertrags\u00e4rztliche Versorgung: Positronenemissionstomographie (PET); Computertomographie (CT) zum Interim-Staging bei fortgeschrittenen Hodgkin-Lymphomen (Beschlusstext) (last accessed 18 June 2018)."},{"key":"10.3238\/arztebl.2018.0535_ref43","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Kunz R, et al.: GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011; 64: 395\u2013400","DOI":"10.1016\/j.jclinepi.2010.09.012"},{"key":"10.3238\/arztebl.2018.0535_ref44","unstructured":"Follmann M, Barlag H, Klinkhammer-Schalke M, et al.: Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Entwicklung von leitlinienbasierten Qualit\u00e4tsindikatoren. Methodenpapier f\u00fcr das Leitlinienprogramm Onkologie. (last accessed 11 April 2018)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:52:55Z","timestamp":1638798775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2018.0535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,6]]},"references-count":44,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2018.0535","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,6]]}}}